Ron A. Adelman is an American ophthalmologist specializing in retinal and macular diseases. He is chairman of the Department of Ophthalmology at Mayo Clinic Florida, where he oversees clinical, research, and educational programs.
Early life and education.
Adelman earned his undergraduate degree in medicine from the Tehran University of Medical Sciences (TUMS) before pursuing a Master of Public Health (MPH) at the University of California, Berkeley. He then completed his ophthalmology residency at Harvard Medical School-affiliated institutions. He received specialized training through a retinal surgery fellowship at Harvard Medical School, where he received the Fellow of the Year Award in 2000 and the Club Vit Fellow Research Award. He also has a Master of Business Administration (MBA) from the Yale School of Management.
Career.
Adelman joined the Yale School of Medicine in 2001 as an assistant professor and director of the retina service. He later became a professor and served as the Interim Chair of the Department of Ophthalmology and Visual Science and ophthalmologist-in-chief of Yale New Haven Hospital from 2014 to 2016. He also held the position of Vice Chair of Academics and was the Director of the Retina and Macula Center at Yale.
He has served on medical societies including as the President of the Connecticut State Medical Society (CSMS) from 2021–2022, President of the Connecticut Society of Eye Physicians and Surgeons (CSEP) from 2014–2016, and President of the New Haven County Medical Association (NHCMA) from 2017–2019. He has served as the Scientific Director of the European VitreoRetinal Society (EVRS) since 2014, a councilor of the American Academy of Ophthalmology (AAO), and the CME Chair of the Association for Research in Vision and Ophthalmology (ARVO). He is also an examiner for the American Board of Ophthalmology and an associate editor of the American Journal of Ophthalmology.
Research.
His research includes studies on treatments for wet macular degeneration, including an investigation of the effectiveness of intravitreal bevacizumab and ranibizumab in a rat model. He contributed to the development of the inverted internal limiting membrane (ILM) flap technique for macular hole repair. His work also includes research on re-engineering ocular tissues with stem cells and studying the differences in Medicare reimbursement between male and female ophthalmologists.